drug · antibody
zanidatamab
pre_registrationupdated 5mo agoby $JAZZ Jazz Pharmaceuticals plc🔗 ChEMBL
community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and biliary tract neoplasm and 4 investigational indications.
targets
Receptor tyrosine-protein kinase erbB-2
all catalysts(0)
nothing on the calendar yet
Trials studying zanidatamab
- —Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
- phase3Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- phase2Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
- phase3A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- phase2Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
- phase2AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas
- phase2Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- phase2A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
News(9)
- Beyond China: Five other overseas destinations for biopharma dollarsAs geopolitical tensions between the U.S. and China grow increasingly complicated, here are five alternative territories for biotech investments.biospace · 25d ago
- UK regulator halts sales of Tavneos; UniQure seeks approval for Huntington's gene therapyPlus, news about Regeneron, Novocure, Jazz's Ziihera, BioMarin, Ascendis, AstraZeneca, Hutchmed and TScan Therapeutics. Another road bump for Tavneos: The Medicines and Healthcare products Regulato…endpoints · 1mo ago
- Roche nabs expanded FDA approval for diagnostic tied to Jazz’s cancer drugRoche has been given an extended clearance by the FDA for its tests that can find patients eligible to use Jazz Pharmaceuticals’ oncology med Ziihera.fiercebiotech · 1mo ago
- Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ ZiiheraGastroesophageal adenocarcinoma presents the biggest market opportunity for Jazz Pharmaceuticals’ Ziihera, according to Truist Securities, which forecasts peak sales of the drug to reach $2.5 billion.biospace · 1mo ago
- New Jazz cancer drug approval could drive blockbuster salesZiihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.biopharma_dive · 1mo ago
- FDA approves Jazz's Ziihera in frontline gastric cancerJazz Pharmaceuticals’ bispecific antibody Ziihera won a label expansion to treat certain patients with gastric cancer. It’s the first time Ziihera will be marketed to newly diagnosed patients, foll…endpoints · 1mo ago
- Recon: FDA expands labels for J&J’s Imaavy, Jazz's Ziihera; Teva faces Turkish antitrust probe over patent movesWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 1mo ago
- Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhDMichael J. Pishvaian, MD, PhD discusses how biomarker-directed strategies, including HER2, CLDN18.2, and KRAS inhibition, are transforming GI cancer care.onclive · 4mo ago
- Approaching First-Line Treatment in PD-L1 CPS <1 HER2-Positive GEAZanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.onclive · 5mo ago
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that